The FDA has approved Exelixis' (EXEL) cabozantinib thyroid cancer drug. Shares are halted....

|By:, SA News Editor
The FDA has approved Exelixis' (EXEL) cabozantinib thyroid cancer drug. Shares are halted. (previous)